News and Events

Clinical trial researching therapy for esophageal cancers

A clinical trial led by David S. Schrump, M.D., MBA., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination vaccine and drug therapy for esophageal cancers.

New biomaterial enhances cancer vaccine effectiveness to help eliminate cancer in mice

Scientists have created a new type of cancer vaccine approach that uses a biomaterial that attracts immune cells and localizes the delivery of the vaccines. In mice, the biomaterial combined with a cancer vaccine was able to cure 50 to 75% of their tumors.

Steven Rosenberg receives AACR Award for Lifetime Achievement in Cancer Research

The American Association for Cancer Research (AACR) has awarded Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, the AACR Award for Lifetime Achievement in Cancer Research. He is being recognized for his paramount contributions to cancer research and patient care, most notably his pioneering research in establishing cancer immunotherapy as a major treatment strategy for many cancer types. He will receive the award at the 2024 AACR Annual Meeting.

Clinical trial researching BRCA1-Associated Protein-1 mutations

A clinical trial led by David S. Schrump, M.D., M.B.A., FACS, Chief and Senior Investigator in the Thoracic Surgery Branch, is researching a combination drug therapy for BRCA1-Associated Protein-1 mutations.

Clinical trial researching therapy for B-cell lymphoma

A clinical trial led by Kathryn A. Lurain, M.D., M.P.H., Assistant Research Physician in the HIV and AIDS Malignancy Branch, is researching a drug for B-cell lymphoma.

Celebrating CCR Careers: Jonathan R. Keller, Ph.D.

Jonathan R. Keller, Ph.D., an experimental hematologist who discovered interleukin-3 (IL-3) and explored the factors that give rise to leukemia, announces his retirement.

India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration

In October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, approved NexCAR19, an effective, low-cost CAR-T cell therapy. The development of the therapy was made possible by a years-long collaborative journey between the Indian Institute of Technology Bombay and Tata Memorial Centre in Mumbai with NCI researchers at the NIH Clinical Center. As India’s first approved CAR-T cell therapy, the treatment will be manufactured in Mumbai and is affordable for many.

Clinical trial researching therapy for RUNX1 mutations

A clinical trial led by Lea C. Cunningham, M.D., Associate Research Physician in the Immune Deficiency Cellular Therapy Program, is researching a drug for RUNX1 mutations.

An image of mouse colon tissue (blue), proliferating stem cells (green) and PEDF (red). Image credit: Girak Kim, et al.

The liver controls intestinal health through the PEDF protein

A new study reveals how the liver and gut communicate to regulate stem cell expansion in the repair of damaged intestinal tissue. The finding, from the lab of Chuan Wu, M.D., Ph.D., has important implications for a lipid-lowering drug that affects that communication.

Howard A. Young, Ph.D., cutting the ribbon to celebrate the opening of his lab in the 1980s.

Celebrating CCR Careers: Howard A. Young, Ph.D.

Howard A. Young, Ph.D., spent over 40 years researching cytokine gene expression, especially interferons and how they contribute to chronic inflammation and disease. Now, he has announced his retirement.

Breadcrumb